Advertisement

Adjuvant Hormone Therapy for Breast Cancer

  • Andrea K. Shimada
  • João Victor Machado Alessi
  • Bruna Zucchetti
  • Artur Katz
Chapter

Abstract

Estrogen plays a key role in the development of breast cancer, and its blockage is the basis of hormone therapy.

Recommended Reading

  1. 1.
    Brufsky A, Bosseman LD, Coradonna R, Haley BB, Jones CM, Moore HC, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozol: Z-FAST Study 36-month follow-up results. Clin Breast Cancer. 2009;9(2):77–85. Patients receiving adjuvant letrozole were randomized (301 in each group) to receive zoledronic acid early or late. After 12 months, bone densitometry showed a 4.4% higher lumbar spine density and, in the hip, 3.3% higher in the early treatment group. Early use of zoledronic acid prevents loss of bone mass in postmenopausal women using adjuvant letrozole. CrossRefGoogle Scholar
  2. 2.
    Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of estrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–16. Available from:  https://doi.org/10.1016/S0140-6736(12)61963-1. Patients receiving adjuvant tamoxifen were randomized to discontinue treatment after 5 years or completing 10 years regardless of their age or menopausal status. Treatment for 10 years was associated with a significant reduction in the risk of tumor recurrence and death, and was associated with a small increase in the risk of pulmonary embolism, cardiac ischemia and endometrial neoplasia. CrossRefGoogle Scholar
  3. 3.
    Goss PE, Ingle JN, Printchard KI, Robert NJ, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375:209–19. The MA.17R study evaluated the impact of extending the use of letrozole for an additional 5 years versus placebo. 1918 patients were included and those who received extended adjuvant showed increased disease-free survival with a 34% reduction in recurrence (HR 0.66 and p 0.01). The extent use of letrozole was related to a decrease in the incidence of new contralateral lesion and modest impact on distant relapse. CrossRefGoogle Scholar
  4. 4.
    Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Zuna I, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. 2006;7(12):991–6. A meta-analysis of three clinical studies: ABCSG8, ARNO 95 and ITA with the aim of evaluating whether sequential treatment with anastrozole after 2–3 years of tamoxifen would be more effective than the continuation of tamoxifen for 5 years. Sequential treatment showed an increase in progression-free survival (HR 0.59, CI 0.48–0.74), distance free survival (HR 0.61, IC: 0.45–0.83) and overall survival (HR 0.71, CI 0.52–0.98). CrossRefGoogle Scholar
  5. 5.
    Prudence A, Francis MD, Meredith M, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372:436–46. A combined analysis of 4690 women treated with ovarian suppression plus exemestane or tamoxifen showed an advantage for combination with AI with disease-free survival at 5 years of 91.1% versus 87.3% (p < 0.01). The results were more robust when observed the population of women under 35 years (83.4% versus 78%). CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Andrea K. Shimada
    • 1
  • João Victor Machado Alessi
    • 1
  • Bruna Zucchetti
    • 1
  • Artur Katz
    • 1
  1. 1.Clinical OncologySírio-Libanês HospitalSão PauloBrazil

Personalised recommendations